-
Mashup Score: 3Selinexor Paves the Way for More Affordable, Effective Treatment Options in Myelofibrosis - 1 month(s) ago
Joseph M. Scandura, MD, PhD, discusses the importance of research with single-agent selinexor in JAK inhibitor–naive myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4Myelofibrosis Treatment Advances Rely on Past Developments to Drive Future Innovation - 1 month(s) ago
Idoroenyi Amanam, MD, discusses JAK inhibitor–associated AE management and considerations for the future use of stem cell transplant in myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Idoroenyi Amanam, MD, discusses JAK inhibitor–associated AE management and considerations for the future use of stem cell transplant in myelofibrosis. @aMyeloidPersona @cityofhope #mpnsm #oncology https://t.co/TEE88k0lQB
-
-
Mashup Score: 6Subanalysis Supports Imetelstat for Transfusion-Dependent Low- to Intermediate-1–Risk MDS - 4 month(s) ago
Mikkael A. Sekeres, MD, discusses the FDA approval of imetelstat for patients with low- to intermediate-1–risk MDS, highlighting data from a subanalysis.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Subanalysis Supports Imetelstat for Transfusion-Dependent Low- to Intermediate-1–Risk MDS @MikkaelSekeres @SylvesterCancer @UMiamiHealth #mpnsm #oncology https://t.co/rhiQX53m3v
-
-
Mashup Score: 6Subanalysis Supports Imetelstat for Transfusion-Dependent Low- to Intermediate-1–Risk MDS - 4 month(s) ago
Mikkael A. Sekeres, MD, discusses the FDA approval of imetelstat for patients with low- to intermediate-1–risk MDS, highlighting data from a subanalysis.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Subanalysis Supports Imetelstat for Transfusion-Dependent Low- to Intermediate-1–Risk MDS @MikkaelSekeres @SylvesterCancer @UMiamiHealth #mpnsm #oncology https://t.co/rhiQX53m3v
-
-
Mashup Score: 3Subanalysis Supports Imetelstat for Transfusion-Dependent Low- to Intermediate-1–Risk MDS - 5 month(s) ago
Mikkael A. Sekeres, MD, discusses the FDA approval of imetelstat for patients with low- to intermediate-1–risk MDS, highlighting data from a subanalysis.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Subanalysis Supports Imetelstat for Transfusion-Dependent Low- to Intermediate-1–Risk MDS @MikkaelSekeres @SylvesterCancer @UMiamiHealth #mpnsm #oncology https://t.co/rhiQX53m3v
-
-
Mashup Score: 1JAK Inhibitor–Based Combinations Could Represent the Next Frontier in Myelofibrosis - 6 month(s) ago
Ashwin Kishtagari, MD, discusses the investigation of JAK inhibitor–based combinations in myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
JAK Inhibitor–Based Combinations Could Represent the Next Frontier in Myelofibrosis @VUMC_Cancer #mpnsm #oncology https://t.co/cmm6BNe8ti
-
-
Mashup Score: 1JAK Inhibitor–Based Combinations Could Represent the Next Frontier in Myelofibrosis - 6 month(s) ago
Ashwin Kishtagari, MD, discusses the investigation of JAK inhibitor–based combinations in myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
JAK Inhibitor–Based Combinations Could Represent the Next Frontier in Myelofibrosis @VUMC_Cancer #mpnsm #oncology https://t.co/cmm6BNe8ti
-
-
Mashup Score: 6Navigating the Growing Landscape of JAK Inhibitors in Myelofibrosis - 6 month(s) ago
Ashwin Kishtagari, MD, discusses the treatment of patients with myelofibrosis following progression on ruxolitinib.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Navigating the Growing Landscape of JAK Inhibitors in Myelofibrosis @AshKishtagari @VUMC_Cancer #mpnsm #oncology https://t.co/yU5jEW4UIA
-
-
Mashup Score: 6Navigating the Growing Landscape of JAK Inhibitors in Myelofibrosis - 6 month(s) ago
Ashwin Kishtagari, MD, discusses the treatment of patients with myelofibrosis following progression on ruxolitinib.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Navigating the Growing Landscape of JAK Inhibitors in Myelofibrosis @AshKishtagari @VUMC_Cancer #mpnsm #oncology https://t.co/yU5jEW4UIA
-
-
Mashup Score: 1JAK Inhibitor–Based Combinations Could Represent the Next Frontier in Myelofibrosis - 6 month(s) ago
Ashwin Kishtagari, MD, discusses the investigation of JAK inhibitor–based combinations in myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
JAK Inhibitor–Based Combinations Could Represent the Next Frontier in Myelofibrosis @VUMC_Cancer #mpnsm #oncology https://t.co/cmm6BNe8ti
-
Joseph M. Scandura, MD, PhD, discusses the importance of research with single-agent selinexor in JAK inhibitor–naive myelofibrosis. @DrJoeScandura @nyphospital #mpnsm #Oncology https://t.co/73JqfOALz4